Grifols (GIFLF) Revenue Growth (3y) (2013 - 2024)
Powered by 
Analysis
Grifols (GIFLF) Revenue Growth (3y) (2013 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 12.90% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 5.75% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 10.17% |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 10.76% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 77.85% |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | -25.02% |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 59.40% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 3.66% |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 458.24% |
| Dec 31, 2021 | -77.18% |
| Dec 31, 2020 | -78.76% |
| Mar 31, 2020 | 8.07% |
| Dec 31, 2019 | 25.22% |
| Mar 31, 2019 | 7.52% |
| Dec 31, 2018 | 47.33% |
| Sep 30, 2018 | 7.19% |
| Jun 30, 2018 | 6.09% |
| Mar 31, 2018 | 6.99% |
| Dec 31, 2017 | 7.89% |
| Jun 30, 2017 | 936.97% |
| Mar 31, 2017 | 1.13% |
| Dec 31, 2016 | 357.40% |
| Sep 30, 2016 | 8.16% |
| Jun 30, 2016 | 7.21% |
| Mar 31, 2016 | 5.42% |
| Dec 31, 2015 | 277.14% |
| Sep 30, 2015 | 10.35% |
| Jun 30, 2015 | 9.50% |